$heff's $tation of $tocks & $olid DD

[oldberkeley]

ABT scientists and execs are not stupid; as many have pointed out, the timing of their announcement certainly suggests that they feel approval is likely and they wanted to put their cards on the table now.

Many, many bios with good, approved drugs; unfortunately, the market says, "That's nice. Now how are you going to sell it?"

That's DEPO's problem here.